| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6168473 | Urology | 2011 | 6 Pages |
Abstract
T-BEP did not improve PFS in patients with poor-prognosis NSGCT. The administration of T-BEP from cycle 1 resulted in excessive toxicity but was administered safely from cycle 2.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
A. Tryakin, M. Fedyanin, D. Kanagavel, I. Fainstein, J. Sergeev, B. Polockij, V. Matveev, T. Zakharova, A. Garin, S. Tjulandin,